Advertisement
Home »

#VisualAbstract: Chronic Lymphocytic Leukemia (CLL) therapy with Ibrutinib and Venetoclax guided by measurable residual disease improves progression-free survival

Feb 01, 2024

ABOUT THE CONTRIBUTORS

Advertisement
Advertisement